More than 40% of women with signs and symptoms of ischemia undergoing coronary angiography have no obstructive coronary artery disease (CAD). Evidence from the Women’s Ischemia Syndrome Evaluation (WISE) study indicates that many have coronary microvascular dysfunction (CMD) defined as abnormal responses to invasive testing of endothelial and nonendothelial macro- and microvascular pathways. These women are at higher risk of major adverse cardiac events compared with similar women with normal responses to such invasive testing and asymptomatic women. At 5.4-year follow-up, adverse events were detected, including cardiac death, stroke, and new onset heart failure, in particular among women with reduced invasive coronary flow reserve (CFR) to adenosine. Noninvasive methods for defining the presence of CMD could be of importance in guiding symptom management and potentially prevention of subsequent cardiac events.

Background—Women with signs and symptoms of ischemia and no obstructive coronary artery disease often have coronary microvascular dysfunction (CMD), diagnosed by invasive coronary reactivity testing (CRT). Although traditional noninvasive stress imaging is often normal in CMD, cardiac MRI may be able to detect CMD in this population.

Methods and Results—Vasodilator stress cardiac MRI was performed in 118 women with suspected CMD who had undergone CRT and 21 asymptomatic reference subjects. Semi-quantitative evaluation of the first-pass perfusion images was completed to determine myocardial perfusion reserve index (MPRI). The relationship between CRT findings and MPRI was examined by Pearson correlations, logistic regression, and sensitivity/specificity. Symptomatic women had lower mean pharmacological stress MPRI compared with reference subjects (1.71±0.43 versus 2.23±0.37; P<0.0001). Lower MPRI was predictive of ≥1 abnormal CRT variables (odds ratio =0.78 [0.70, 0.88], P<0.0001, c-statistic 0.78 [0.68, 0.88]). An MPRI threshold of 1.84 predicted CRT abnormality with sensitivity 73% and specificity 74%.

Conclusions—Noninvasive cardiac MRI MPRI can detect CMD defined by invasive CRT. Further work is aimed to optimize the noninvasive identification and management of CMD patients.

Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00832702. (Circ Cardiovasc Imaging. 2015;8:e002481. DOI: 10.1161/CIRCIMAGING.114.002481.)

Key Words: magnetic resonance imaging ▪ microvascular angina ▪ myocardial perfusion ▪ women
Cardiac MRI (CMRI) stress perfusion can detect myocardial perfusion abnormalities caused by obstructive CAD with advantages of high spatial resolution without ionizing radiation. Semi-quantitative evaluation of the first-pass perfusion images can be used to calculate an indexed ratio of perfusion-time intensity curve upslopes as a measure of myocardial perfusion reserve index (MPRI) in response to vasodilator stress. We, and others, have reported in prior pilot studies differences between symptomatic subjects and reference subjects with open coronary arteries and women with systemic lupus erythematosus and chest pain. CMRI can be readily performed in a clinical setting with current 1.5 T systems and commercially available software.

We studied a new large cohort of women with symptoms and signs of myocardial ischemia in the absence of obstructive epicardial CAD and determined noninvasive cardiac MPRI in subjects and asymptomatic controls with comparison to invasive CRT.

Methods

This was a part of the National Heart, Lung, and Blood Institute-sponsored prospective multicenter WISE-Coronary Vascular Dysfunction (WISE-CVD) study. All studies were performed at Cedars-Sinai Medical Center or the University of Florida, Gainesville, between January 2009 and June 2012 where institutional review boards approved the project and all participants provided written informed consent.

The WISE subjects were women with signs and symptoms of ischemia, had clinically indicated invasive CRT, and underwent CMRI. Exclusion criteria were acute myocardial infarction within 30 days, percutaneous coronary intervention, coronary artery bypass grafting, or valve surgery subsequent to baseline qualifying coronary angiogram and any conditions that precluded accurate or safe testing or follow up, specifically: obstructive CAD ≥50% luminal diameter stenosis in ≥1 epicardial coronary artery, acute coronary syndrome, primary valvular heart disease with need for valve repair or replacement, concurrent cardiogenic shock, prior noncardiac illness with estimated life expectancy <4 years, chest pain with known nonischemic pathogenesis (eg, pericarditis, pneumonia, esophageal spasm), contraindications to CMRI (pacemaker, other electronic device, severe claustrophobia), severe asthma (vasodilator stress contraindicated), severe renal impairment (gadolinium contrast contraindicated), Long-acting nitrates, short-acting calcium-channel blockers, α-blockers, β-blockers, and angiotensin-converting enzyme-inhibitors-II-receptor antagonists were withdrawn 24 hours, and long-acting calcium-channel blockers were held for 48 hours before CRT and CMRI testing. Sublingual nitroglycerin was not taken within 4 hours before testing, and participants were caffeine-free and nicotine-free for 24 hours before vasodilator stress. Reference subjects were age-matched women without symptoms or cardiac risk factors who had a normal maximal Bruce-protocol exercise treadmill stress test.

Coronary Reactivity Testing

CRT was performed using a standardized protocol. Briefly, a Doppler guidewire was placed in the proximal left anterior descending coronary artery and coronary endothelial and nonendothelial pathways were tested. Microvascular coronary function was assessed from coronary flow, with intracoronary adenosine (18 and 36 μg) used to achieve hyperemia. CFR was derived from the ratio of the average peak velocity of blood flow at maximal hyperemia and average peak velocity at rest as previously described. We have previously shown that this ratio closely approximates volumetric CFR in similar women enrolled in WISE. Coronary endothelial function was assessed by graded intracoronary infusions of acetylcholine (0.182 and 18.2 μg/mL), 2 ml infused over 3 minutes. These concentrations of 10⁻⁶ and 10⁻⁴ mol/L were infused to obtain effective coronary concentrations of 10⁻⁵ and 10⁻³ mol/L, respectively. Coronary macrovascular nonendothelial function was tested using 200 μg of intracoronary nitroglycerin. Hemodynamic data, Doppler velocities, and coronary cine angiography were obtained after each infusion.

CMRI Protocol

A standardized CMRI protocol and equipment were used (1.5 T Magnetom Avanto; Siemens Healthcare, Erlangen, Germany). First-pass contrast perfusion imaging was performed using gadolinium contrast of 0.05 mmol/L/kg (Gadodiamide; Omniscan, Amersham, Piscataway, NJ) infused at 4 ml/s, followed by 20 mL saline at 4 mL/s. Vasodilator stress was adenosine 140 μg/kg/min infused for 2 minutes into the arm contralateral to the contrast injection, before first-pass perfusion imaging, and continued until completion of the perfusion imaging data acquisition. Resting first-pass perfusion was done 10 minutes later.

Perfusion images were obtained in 3 left ventricular (LV) short-axis imaging slices (basal, mid, and distal LV slice positions) with the following parameters: Gradient echo–EPI hybrid sequence, TR per slice 148 ms, TE 1.1 ms, BW 1420 Hz/pixel, echo train length 4, readout flip angle 20°, slice thickness 8 mm, image matrix 160×70 pixels, in-plane resolution 2.7×2.2 mm², parallel imaging (GRAPPA) factor 2, imaging 3 slices every heartbeat. In the event of a peak stress heart rate of >120 bpm, 2 slices were obtained during stress first-pass imaging with exclusion of the distal LV slice position.

LV function and delayed enhancement imaging were performed using a standardized approach, as previously described.

Data Analysis

CRT was interpreted blinded to clinical data by an expert reader experienced in performance and interpretation of CRT (J. Petersen) in a dedicated core laboratory using our published methods. Coronary artery diameter was measured 5 mm distal to the tip of the Doppler wire. Four CRT measures were assessed: (1) abnormal endothelial function defined as a change in epicardial coronary artery diameter ≥20% in response to a maximum dose of acetylcholine (ΔACH)²; (2) abnormal CFR, defined as CFR <2.5 in response to adenosine¹: (3) abnormal microvascular endothelial dysfunction, defined as an increase in coronary blood flow (CBF) ≤50% in response to acetycholine (ΔCBF); (4) abnormal nonendothelial function defined as a change in epicardial coronary artery diameter ≤20% in response to nitroglycerin (ΔNTG). CBF was determined as π(artery coronary diameter/2)x(average peak velocity/2). An abnormal CRT was defined as ≤21 abnormal measures. Reference subjects were considered to have normal CRT.

CMRI data were interpreted by computer-based analysis by expert readers experienced in performance and interpretation of CMRI (L-E.J. Thomson, M. Agarwal, A. Haft-Baradaran, J. Wei) blinded to clinical and CRT data in a dedicated core laboratory. CAAS MRV 3.4 (PIE Medical Imaging) was used for analysis of the MPRI. The endocardial and epicardial contours were manually defined and adjusted to sample data from LV myocardium alone. Care was taken to exclude blood pool activity and to exclude any linear dark rim artifact at the LV cavity/endocardial border. The LV cavity region of interest was manually adjusted to include the region of maximal signal intensity within the cavity and to exclude papillary muscle. MPRI was defined as MPRI=RUIstress/RUIrest. RU is defined as the ratio between the maximum upslope of the first-pass myocardial perfusion time-intensity curve divided by the maximum upslope of the first-pass LV cavity time-intensity curve. An American Heart Association 16-segment model was used (true apex not imaged); mean MPRI was the average of 16 segments. In the case of 2-slice image data being acquired as a result of high stress heart rate, data were recorded for 12 segments, and mean MPRI was the average of 12 segments. Subendocardial MPRI, subepicardial MPRI, and whole (transmural) MPRI were calculated.

LV mass and volumes were assessed by manually tracing the epicardial and endocardial borders of short-axis cine images. Stroke volume was calculated as end-diastolic volume minus end-systolic
volume. Ejection fraction was calculated as stroke volume divided by end-diastolic volume. Stress and rest perfusion were scored visually by consensus of 2 blinded readers, using a 4-point 16-segment system. Summed stress score was the sum of visually abnormal segments. Delayed enhancement images were read by an experienced investigator to identify and describe areas of late enhancement.

**Statistical Analysis**

Values are expressed as mean±standard deviation or percentages as indicated, and the t test or χ² statistic was used to evaluate differences in WISE versus reference control women. For diagnostic measures, medians and interquartile ranges are also reported, and Pearson correlation coefficients (P values) were used to report associations among these measures. The Jonckheere–Terpstra test for continuous variables was used to test whether the distribution of MPRI differs across increasing numbers of abnormal CRT variables or increasing numbers of cardiac risk factors.

CRT was considered normal if all 4 CRT measures were normal. CRT was considered abnormal if ≥1 measures were abnormal. Logistic regression was used to estimate the probability of abnormal CRT given MPRI; because of the small range of MPRI values such that a unit change represents a large relative change, MPRI was multiplied by 10 for this analysis. We used ROC curve analysis to identify the optimal threshold in the MPRI for predicting an abnormal CRT test. The threshold was chosen that gave the largest area under the ROC curve, which represented a trade-off between sensitivity and specificity. The threshold was chosen that gave the largest area under the ROC curve, which represented a trade-off between sensitivity and specificity. The area under the ROC curve and 95% confidence intervals are reported to indicate the probability that a randomly selected diseased case (woman with abnormal CRT) will have a lower MPRI measurement than a randomly selected control. A P value <0.05 was considered statistically significant. SAS version 9.3 was used for all analyses.

**Results**

Pertinent demographic characteristics are summarized in Table 1. All WISE subjects were symptomatic, most (88%) with angina and the remainder with dyspnea. Hypertension, family history, and prior smoking were frequent, and relatively few were diabetic (9%) or currently smoking (6%). WISE subjects had a greater body mass index (BMI) than reference subjects.

Results of CRT are summarized in Table 2 and demonstrate abnormal coronary diameter changes in response to acetycholine and nitroglycerin. Overall, among the WISE subjects, 95% had CMD defined as ≥1 CRT abnormality. The median time (interquartile ranges) between CRT and CMRI was 28 days (14, 46).

CMRI stress testing was completed without complications. All CMRI scans were included in analysis. There were no differences between WISE subjects and reference subjects in terms of baseline rest or vasodilator stress heart rate and blood pressure (Table 3).

The mean transmural MPRI was lower in WISE subjects compared with reference subjects (1.71±0.43 versus 2.23±0.37, P<0.0001). Differences between WISE subjects and reference subjects remained significant by examining midventricular short-axis segments alone (1.75±0.48 versus 2.23±0.45, P<0.0001) and by examining subendocardial and subepicardial MPRI (Table 4). There was no difference between the 9 subjects with 12-segment MPRI data (peak heart rate precluded 3-slice imaging during pharmacological stress) and 130 subjects with 16-segment data (mean MPRI 1.88±0.45 versus 1.78±0.46, P=0.54). Visual evaluation of images did not reveal any significant difference between groups. The ratio of mass/volume was greater in WISE subjects; all subjects had normal LV ejection fraction. There were 6/118 WISE subjects with myocardial fibrosis on delayed enhancement imaging, mean 6.16±3.38 g, range 3.2 to 11.2 g. Fibrosis was subendocardial in 4 and a nonischemic-type distribution of late enhancement was present in 2 WISE subjects. No reference subject had late enhancement.

Relationships between CRT variables and mean MPRI are summarized in Table 5 and demonstrate modest statistically significant positive correlations between individual CRT variables and MPRI. MPRI did not significantly differ between subjects with and without CRT abnormality (mean MPRI 1.71±0.42 versus 1.76±0.55, P=0.76).

There was a trend toward decreasing MPRI as the number of abnormal CRT variables increased (Figure 1). This trend was examined in women who had all CRT variables for analysis and included the reference subjects (assumed to have normal CRT). A similar trend toward decreasing MPRI was also present as the number of CAD risk factors increased among WISE subjects (Figure 2).

**ROC Analysis**

This analysis included a subgroup of 82 WISE subjects who had all 4 CRT variables available for analysis as well.
as reference subjects for whom normal CRT was assumed in all. Logistic regression to estimate the ability of the whole mean MPRI to predict a normal CRT yielded an odds ratio of 0.78 (95% confidence interval = 0.70, 0.88), \( P < 0.0001 \). This means that there is a 22% relative increase in the probability of an abnormal CRT (any pathway abnormality) for each 0.1 decrease in the MPRI. The area under the curve of the ROC was 0.78 (95% confidence interval 0.68, 0.88; Figure 3). An MPRI threshold of 1.84 in this analysis predicted CMD status with sensitivity 73% (95% confidence interval = 64, 82) and specificity 74% (95% confidence interval = 58, 90).

**Discussion**

Our results show that noninvasive CMRI MPRI is useful for detection of CMD determined by invasive CRT in women. Women with CMD defined by presence of abnormal invasive CRT have reduced MPRI with vasodilator stress first-pass perfusion CMRI compared with an age-matched reference group. The differences between groups were observed in all LV regions, with a gradient between subepicardial and subendocardial MPRI in both WISE and reference subjects. There is a trend toward lower MPRI among women with extensive CRT abnormalities. In this selected population, a threshold MPRI value of 1.84 predicted CMD status with moderate sensitivity (73%) and specificity (74%).

A growing body of evidence supports the presence of CMD among women with symptoms and signs of ischemia in the absence of obstructive epicardial CAD. It is likely that CMD encompasses a spectrum of disorders of coronary endothelial and nonendothelial-dependent vascular reactivity. A multitude of factors have been suggested as causative factors in CMD, including risk factors for atherosclerotic disease, hormonal, and structural factors.

CMD is hypothesized to be a generalized process that may result in patchy but more or less generalized subendocardial myocardial ischemia as opposed to the highly regional location of ischemia resulting from obstructive epicardial CAD.\(^1,^6\) Standard noninvasive imaging (echo/nuclear stress testing) is often normal in patients with CMD without obstructive CAD because of a lack of regional vascular territory ischemia that is characteristic of obstructive CAD.\(^6\) The reference standard for diagnosis is CRT that is an invasive procedure for patients with persisting symptoms of ischemia in the absence of obstructive CAD. CMRI is potentially a noninvasive tool for diagnosis of CMD in this population.

CMRI perfusion abnormalities have been described in patients with angina and in the absence of obstructive CAD. Impairment of myocardial perfusion reserve has also been documented in some asymptomatic individuals with multiple cardiac risk factors in the Multi-Ethnic Study of Atherosclerosis, in asymptomatic patients with hypertrophic cardiomyopathy, and in women with chest pain and systemic lupus erythematosus.\(^10,^17\) A variety of CMRI techniques have been reported in single center studies of small groups of patients, and these vary widely in terms of technical complexity, clinical applicability, and system field strength (3.0 T versus 1.5 T). Relatively simple approaches include visual detection of subendocardial first-pass hypoperfusion,\(^1,^8\) measurement of perfusion upslope curve steepness,\(^3\) and calculation of a ratio of stress to rest upslope\(^4\) in response to vasodilator, dobutamine, or cold pressor stress. More complex approaches involve calculation of absolute myocardial blood flow reserve,\(^19\) detection of diffuse myocardial fibrosis,\(^20\) noninvasive measurement of cellular

### Table 2. CRT Measures (n=118)

<table>
<thead>
<tr>
<th>Measure (Definition of Normal)</th>
<th>N</th>
<th>Mean±SD</th>
<th>Median (IQR)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACH (&lt;0% increase)</td>
<td>96</td>
<td>-2.4±14.6</td>
<td>-1.0(-10.4, 6.6)</td>
<td>-43.4—47.3</td>
</tr>
<tr>
<td>CFR (≥2.5)</td>
<td>110</td>
<td>2.62±0.61</td>
<td>2.60(2.20, 2.80)</td>
<td>1.3—4.7</td>
</tr>
<tr>
<td>CBF (&gt;50% increase)</td>
<td>86</td>
<td>68±86</td>
<td>46(10, 101)</td>
<td>-68—456</td>
</tr>
<tr>
<td>NTG (&gt;20% increase)</td>
<td>98</td>
<td>12.4±12.1</td>
<td>10.2(3.8, 20.2)</td>
<td>-14.6—52.1</td>
</tr>
</tbody>
</table>

- \( \Delta \text{ACH} \) indicates % diameter change in response to acetylcholine; \( \text{CFR} \), coronary flow reserve in response to adenosine; \( \text{CRT} \), coronary reactivity testing; \( \Delta \text{CBF} \), % coronary blood flow change in response to acetylcholine; \( \text{IQR} \), interquartile range; and \( \Delta \text{NTG} \), % diameter change in response to nitroglycerin.

### Table 3. CMRI Hemodynamic Variables (WISE=118, Reference=21)

<table>
<thead>
<tr>
<th>Measure</th>
<th>Mean±SD</th>
<th>Median (IQR)</th>
<th>Range</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rest HR</td>
<td></td>
<td></td>
<td></td>
<td>0.09</td>
</tr>
<tr>
<td>WISE subjects</td>
<td>68±10</td>
<td>68 (60,74)</td>
<td>40—103</td>
<td></td>
</tr>
<tr>
<td>Reference subjects</td>
<td>64±8</td>
<td>62 (57,69)</td>
<td>54—82</td>
<td></td>
</tr>
<tr>
<td>Peak stress HR</td>
<td></td>
<td></td>
<td></td>
<td>0.52</td>
</tr>
<tr>
<td>WISE subjects</td>
<td>94±17</td>
<td>96 (81,106)</td>
<td>51—127</td>
<td></td>
</tr>
<tr>
<td>Reference subjects</td>
<td>97±13</td>
<td>97 (87,106)</td>
<td>72—120</td>
<td></td>
</tr>
<tr>
<td>Rest SBP</td>
<td></td>
<td></td>
<td></td>
<td>0.76</td>
</tr>
<tr>
<td>WISE subjects</td>
<td>129±22</td>
<td>129 (113,140)</td>
<td>81—193</td>
<td></td>
</tr>
<tr>
<td>Reference subjects</td>
<td>128±20</td>
<td>129 (116,138)</td>
<td>96—176</td>
<td></td>
</tr>
<tr>
<td>Peak stress SBP</td>
<td></td>
<td></td>
<td></td>
<td>0.29</td>
</tr>
<tr>
<td>WISE subjects</td>
<td>134±27</td>
<td>130 (118,148)</td>
<td>50—241</td>
<td></td>
</tr>
<tr>
<td>Reference subjects</td>
<td>129±17</td>
<td>127 (117,141)</td>
<td>106—163</td>
<td></td>
</tr>
<tr>
<td>Rest RPP</td>
<td></td>
<td></td>
<td></td>
<td>0.17</td>
</tr>
<tr>
<td>WISE subjects</td>
<td>8749±1870</td>
<td>8578 (7424,9880)</td>
<td>5040—15440</td>
<td></td>
</tr>
<tr>
<td>Reference subjects</td>
<td>8145±1667</td>
<td>7840 (6820,2024)</td>
<td>5454—12144</td>
<td></td>
</tr>
</tbody>
</table>

CMRI indicates cardiac MRI; HR, heart rate; IQR, interquartile range; RPP, rate pressure product; SBP, systolic blood pressure; and WISE, Women’s Ischemia Syndrome Evaluation.

### Table 4. CMRI Measures

<table>
<thead>
<tr>
<th>Measure</th>
<th>WISE Subjects (n=118) Mean±SD</th>
<th>Reference Subjects (n=21) Mean±SD</th>
<th>( P ) Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole MPRI</td>
<td>1.71±0.43</td>
<td>2.23±0.37</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Subendocardial MPRI</td>
<td>1.55±0.39</td>
<td>2.01±0.35</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Subepicardial MPRI</td>
<td>1.79±0.45</td>
<td>2.38±0.41</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Summed stress score</td>
<td>6.68±5.62</td>
<td>4.45±4.97</td>
<td>0.09</td>
</tr>
<tr>
<td>Ejection fraction, %</td>
<td>67.19±7.05</td>
<td>69.4±4.26</td>
<td>0.17</td>
</tr>
<tr>
<td>LV EDV, mL</td>
<td>121.96±25.54</td>
<td>131.71±28.16</td>
<td>0.11</td>
</tr>
<tr>
<td>LV mass, g</td>
<td>91.94±17.07</td>
<td>85.69±12.04</td>
<td>0.11</td>
</tr>
<tr>
<td>Mass/volume, g/mL</td>
<td>0.77±0.14</td>
<td>0.68±0.12</td>
<td>0.0064</td>
</tr>
</tbody>
</table>

CMRI indicates cardiac MRI; EDV, end-diastolic volume; LV, left ventricle; MPRI, myocardial perfusion reserve index; and WISE, Women’s Ischemia Syndrome Evaluation.
oxygenation, or the detection of earliest abnormalities in diastolic filling. Studies also vary widely in the method of selection of subjects; many do not have a control group.

These results extend our previously published pilot data that showed the same difference in MPRI between a different group of women with CMD defined by invasive CRT compared with control subjects. The current study extends those results to a new and larger cohort of women with CMD from 2 sites supporting the scalability of these CMR examinations. Study inclusion was on the basis of symptoms and signs of myocardial ischemia in the absence of obstructive epicardial CAD, with entry criteria being broader than prior pilot data. Again, we documented a lower MPRI compared with reference women. Additionally, in this much larger cohort, we observed a relationship between presence of CRT abnormalities and MPRI measured noninvasively. Interestingly, by simple visual analysis, no significant differences were noted between groups. It is likely that variable human light-level sensory thresholds as well as possible artifacts on images contributed to inability to discriminate between WISE subjects and reference subjects using unaided visual scoring.

Our study builds on previous work from Panting et al who first emphasized the importance of a lack of increment in subendocardial perfusion index during adenosine stress in symptomatic subjects without obstructive CAD, not observed in controls. They were unable to show a difference between groups in terms of the ratio of stress to rest perfusion (MPRI); however, they noted differences of borderline significance in both subendocardial and subepicardial MPRI in their small sample of 20 patients with 10 controls. Our study had greater power to detect differences between groups and used somewhat different criteria for selection of both subjects and the reference group. Nevertheless, we observed a difference in response to adenosine vasodilator stress between the subjects and reference groups, expressed in terms of MPRI.

Our findings and methods are similar to those of Vermeltfoort et al who reported on 20 subjects with clinically defined syndrome X using adenosine first-pass perfusion at 1.5 T and noted a mean transmural myocardial MPRI 1.83±0.5, subendocardial MPRI 1.67±0.38, and subepicardial MPRI 1.98±0.64. They noted an increment in first-pass perfusion upslope in response to adenosine that could be measured in endocardial and epicardial regions and concluded that they had failed to replicate the observations of Panting et al who had emphasized the importance of the lack of a subendocardial stress perfusion response in subjects with syndrome X. However, Vermeltfoort et al did not have a control group for comparison.

A previous 3 T CMRI study of 18 patients with clinically defined syndrome X and 14 controls by Karamitsos et al did not find differences in either absolute myocardial flow or

<table>
<thead>
<tr>
<th>MPRI</th>
<th>∆ACH R (P Value)</th>
<th>CFR R (P Value)</th>
<th>∆CBF R (P Value)</th>
<th>∆NTG R (P Value)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Whole</td>
<td>0.22(0.029)</td>
<td>0.16(0.084)</td>
<td>0.29(0.005)</td>
<td>0.24(0.016)</td>
</tr>
<tr>
<td>Subendocardial</td>
<td>0.20(0.046)</td>
<td>0.15(0.11)</td>
<td>0.30(0.004)</td>
<td>0.22(0.031)</td>
</tr>
<tr>
<td>Mid-ventricular short axis</td>
<td>0.24(0.016)</td>
<td>0.12(0.19)</td>
<td>0.32(0.002)</td>
<td>0.22(0.03)</td>
</tr>
</tbody>
</table>

∆ACH indicates % diameter change in response to acetylcholine; CFR, coronary flow reserve in response to adenosine; ∆CBF, % coronary blood flow change in response to acetylcholine; CRT, coronary reactivity testing; MPRI, myocardial perfusion reserve index; and ∆NTG, % diameter change in response to nitroglycerin.

![Figure 1](image1.png)  
**Figure 1.** Relationship between MPRI and CRT measures. Boxplot demonstrating trend for decreasing MPRI with increasing numbers of abnormal CRT measures. Data are for CRT in 82 WISE subjects who had all 4 CRT measures and 21 reference subjects. CRT indicates coronary reactivity testing; MPRI, myocardial perfusion reserve index; and WISE, Women's Ischemia Syndrome Evaluation.

![Figure 2](image2.png)  
**Figure 2.** Relationship between MPRI and increasing number of cardiac risk factors. Boxplot demonstrating trend for decreasing MPRI with increasing number of cardiac risk factors. Data are for WISE subjects and reference subjects, excluding one woman with incomplete data. MPRI indicates myocardial perfusion reserve index; WISE, Women’s Ischemia Syndrome Evaluation.
oxygenation between groups. We had a different and larger population of women who were younger and heavier (mean age 55, BMI 30 versus mean age 62, BMI 26). Our inclusion criteria required invasive CRT for characterization of CMD, and our reference group was selected based on absence of physical limitation and ischemia during exercise testing.

The importance of an appropriate control group should be reemphasized. There is a paucity of published data defining what is normal MPRI for stress CMRI using this technique in middle-aged women. Regional heterogeneity in myocardial perfusion has been observed in 3 T studies of absolute myocardial blood flow in healthy human myocardium, and it has been observed that the hyperemic myocardial blood flow response to vasodilator stress is reduced in older versus younger populations. If we had selected a younger, more fit female population as a control group, there would potentially have been a greater difference between groups in terms of MPRI, but study results would have had less applicability to clinical management of a typical symptomatic middle-aged woman.

Limitations

There are several potential limitations to the study. Our WISE population was selected with the absence of obstructive CAD defined by coronary angiography. Obstructive CAD is expected to be associated with lower mean MPRI, vascular territory regional variation in MPRI, and segmental visual perfusion abnormalities. Our results cannot be extrapolated to unselected populations, and the ROC data are not representative of the ability of MPRI to define the presence of obstructive CAD. In this CRT analysis, we used a sensitive threshold for the CBF variable (ΔCBF ≤ 50), understanding that this may reduce specificity for this initial analysis. In addition, the threshold value is data derived, and so the sensitivity and specificity may be overestimated in the absence of validation. We compared subjects from the WISE population to an age-matched group of healthy women because there is a paucity of data defining normal MPRI using this technique in middle-aged overweight women. A merged sample of cases and reference controls was used to extend the range of MPRI values for analyses of the relationships between MPRI and the number of abnormal CRT measures (Figure 1) and number of atherosclerosis risk factors (Figure 2); further work will evaluate this with respect to the proportion of cases in the population. The size of our reference group was relatively small compared with the WISE group, thus inadvertent inclusion of subjects with CMD within the reference group could decrease the ability of CMRI to discriminate between WISE and reference subjects. Our reference group did not have coronary angiography or CRT because of the unacceptable risk of invasive testing without clinical indication. The reference group had lower BMI than WISE subjects, potentially contributing to the observed difference in MPRI between groups. However, DiBella et al reported a similar normal mean MPRI of 2.25±0.59 in a group of asymptomatic volunteers undergoing adenosine stress at 3 T, with mean BMI 30.3±6.5. We chose to use a clinical 1.5 T CMRI scanner and standard commercially available image data analysis software to test the scalability of the method to another center. The imaging used an accelerated pulse sequence with inherent image artifacts, and thus care was taken to avoid incorporation of dark rim artifact within the myocardial region used for semiquantitative analysis. It is possible that inadvertent incorporation of artifact contributed to apparent reduction in subendocardial versus subepicardial MPRI; however, the MPRI was reduced in WISE population compared with reference subjects in both subendocardial and subepicardial regions. Finally, we did not measure absolute myocardial flow, which is most accurately performed at 3 T and requires specialized postprocessing that was not available for routine clinical use. Additionally, it has been demonstrated that semiquantitative measurement of MPRI is more reproducible than measurement of absolute flow.

Implications

Our results demonstrate that noninvasive CMRI MPRI can detect CMD defined by invasive CRT. Analysis of the relationship between noninvasive and invasive CRT suggests that there may be a threshold value for MPRI that will predict likelihood of abnormal invasive CRT in this population. These findings have potential implications for management of women who have persisting chest pain in the absence of obstructive epicardial disease in whom CMD has previously only been identifiable by invasive means. Importantly, the methodology used standard equipment and protocol that is available in most tertiary institutions. Further work is required to define the relationship between noninvasive and invasive measures of myocardial perfusion reserve in this population to optimally identify patients with abnormalities of endothelial and nonendothelial coronary microvascular function. Additional long-term follow-up is needed to determine whether CMRI-derived MPRI testing leads to improved cardiovascular outcomes.
Sources of Funding
This work was supported by contracts from the National Heart, Lung and Blood Institutes, nos. N01-HV-68161, N01-HV-68162, N01-HV-68163, N01-HV-68164, K23HL105787; grants U0164829, U01 HL649141, U01 HL649241, T32HL69751, T32HL116273, R01 HL090957, 1R03AG032631 from the National Institute on Aging; General Clinical Research Center grant MO1-RR00425 from the National Center for Research Resources, UL1TR000124 and UL1TR000604, grants from the Gustavus and Louis Pfeiffer Research Foundation, Danville, NJ; The Women’s Guild of Cedars-Sinai Medical Center, Los Angeles, CA; The Ladies Hospital Aid Society of Western Pennsylvania, Pittsburgh, PA; and QMED, Inc., Lawrence Harbor, NJ; the Edythe L. Broad and the Constance Austin Women’s Heart Research Fellowships, Cedars-Sinai Medical Center, Los Angeles, California; the Barbra Streisand Women’s Cardiovascular Research and Education Program, Cedars-Sinai Medical Center, Los Angeles; The Society for Women’s Health Research (SWHR), Washington, DC; The Linda Joy Pollin Women’s Heart Health Program, and the Erika Glazer Women’s Heart Health Project, Cedars-Sinai Medical Center, Los Angeles.

Disclosures
Thomson, NHLBI; Shufelt, Gilead; Mehta, Gilead; Handberg, Gilead, AstraZeneca, Daiichi Sankyo, Amarin, Daiichi, Mesoblast, ISIS Pharmaceuticals, Esperion Therapeutics, Vessix, Genentech, Cytori, Daiichi-Sankyo, Medtronic, Baxter, United Therapeutics, Sanofi/Aventis, Amgen, Catabasis; Berman, Spectrum Dynamics, Cedars Sinai Medical Center-softwaroyalties, Lantheus, Siemens, Astellas, GE/Amersham, Cardium Therapeutics Inc; Pepine, NIH Study Section of Cardiovascular Sciences Small Business Activities 2RGI CVS-K-10, Lilly/Cleveland Clinic DSMB Member for a Phase II Efficacy and Safety Study of Ly2485459. Medtricel, NHLBI Study Section for Progenitor Cell Biology Consortium, NHLBI DSMB Chair for Freedom Trial, Gilead Sciences, Inc, Pfizer, Padavini, Sanofi-Aventis, Fujisawa HealthCare Inc, Baxter, Brigham & Women’s Hospital, AstraZeneca, NIH/NHLBI, Amorcyte/Neostem, Cytori, InfraRedx, NHLBI/NCCR CTSA grant 1UL1RR029890, AHA; Baiere Merz, Research Triangle Institute International, UCSF, Kaiser, Gilead (grant review committee), Garvan State AHA, Allegheny General Hospital, PCNA, Mayo Foundation (lectures; symposiums), Bryn Mawr Hospital, Victor Chang Cardiac Research Institute (Australia), Duke (Consulting, Japanese Circice Society, U of New Mexico, Emory, Practice Pon Communications (lectures), Vox Media (lectures), WISE CVD, FAMRI, RWISE, Normal Control, Microvascular, NIH-SEP.

References


**CLINICAL PERSPECTIVE**

Management of chest pain in women with no obstructive coronary artery disease is a challenge for physicians. Estimates from the NHLBI-sponsored Women’s Ischemia Syndrome Evaluation (WISE) database show that there are ≥3 to 4 million patients in the United States with signs and symptoms of ischemia, despite no obstructive coronary artery disease. This group, more frequently women, have reduced quality of life, psychological distress, and a higher risk of adverse cardiac events. WISE 5.4-year follow-up demonstrated adverse events, including cardiac death, myocardial infarction, stroke, and new onset heart failure, and these adverse events were significantly associated with reduced coronary flow reserve to intracoronary adenosine. Coronary microvascular dysfunction (CMD) appears to contribute to chest pain and ischemia in these women, and its diagnosis is important for guiding symptom management and potentially preventing subsequent adverse events. Invasive coronary reactivity testing is regarded as gold standard for CMD evaluation, although noninvasive diagnosis of CMD has been inadequate. In this article, we investigated cardiac MRI as a noninvasive method for CMD evaluation. We demonstrate that a semiquantitative approach with measurement of myocardial perfusion reserve index can detect CMD in women without obstructive coronary artery disease. Women with CMD defined by presence of abnormal invasive coronary reactivity testing have reduced myocardial perfusion reserve index compared with a carefully selected reference group. Because the methodology uses standard equipment and protocol that is available in most tertiary institutions, noninvasive MPRI measurement may be useful in the diagnosis and management of women who have persistent chest pain in the absence of obstructive coronary artery disease.
Cardiac Magnetic Resonance Myocardial Perfusion Reserve Index Is Reduced in Women With Coronary Microvascular Dysfunction: A National Heart, Lung, and Blood Institute-Sponsored Study From the Women's Ischemia Syndrome Evaluation


_Circ Cardiovasc Imaging_. 2015;8:
doi: 10.1161/CIRCIMAGING.114.002481

_Circulation: Cardiovascular Imaging_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-9651. Online ISSN: 1942-0080

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circimaging.ahajournals.org/content/8/4/e002481

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation: Cardiovascular Imaging_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation: Cardiovascular Imaging_ is online at:
http://circimaging.ahajournals.org/subscriptions/